Comparison of Serum Vitamin D Levels in Clinically Isolated Syndrome Patients

Document Type : Original Article (s)

Authors

1 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Pathology, School of Medicine, Reproductive Sciences and Sexual Health Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Department of Neurology, School of Medicine, Neurosciences Research Center Kashani Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

4 Professor, Infectious Diseases and Tropical Medicine Research Center, Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v43.i835.1306

Abstract

Background: Vitamin D deficiency is considered a modifiable risk factor in Clinically Isolated Syndrome (CIS), and early interventions to correct vitamin D levels may be an effective strategy in the management of these patients. Considering the role of vitamin D in cases of multiple sclerosis (MS), this study was conducted with the aim of comparing the level of vitamin D in patients with CIS and healthy population.
Methods: In this case-control study, the vitamin D levels of 51 patients with CIS and 150 healthy individuals were measured and compared along with demographic and clinical data. Data were entered into analyzed using chi-square, t-test, and logistic regression tests.
Findings: The mean serum level of vitamin D in the patient and control groups was 37.0 ± 13.8 and 38.8 ± 25.1 ng/dL, respectively, and the difference between the two groups was significant (P = 0.042).
Conclusion: It seems that the serum level of vitamin D in patients with CIS is lower than in healthy individuals, suggesting that vitamin D may play a role in the pathogenesis of CIS.

Highlights

Azar Naeimi: Google Scholar 

Vahid Shaygannejad: Google Scholar 

Azar Baradaran:  Google Scholar 

Keywords

Main Subjects

References

  1. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol 2012; 11(2): 157-69.
  2. O’Connell K, Sulaimani J, Basdeo SA, Kinsella K, Jordan S, Kenny O, et al. Effects of vitamin D3 in clinically isolated syndrome and healthy control participants: A double-blind randomised controlled trial. Mult Scler J Exp Transl Clin 2017; 3(3): 2055217317727296.
  3. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364(9451): 2106-12.
  4. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292-302.
  5. Pardini M, Gualco L, Bommarito G, Roccatagliata L, Schiavi S, Solaro C, et al. CSF oligoclonal bands and normal appearing white matter periventricular damage in patients with clinically isolated syndrome suggestive of MS. Mult Scler Relat Disord 2019; 31: 93-6.
  6. Bommarito G, Bellini A, Pardini M, Solaro C, Roccatagliata L, Laroni A, et al. Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS. Mult Scler 2018; 24(5): 623-31.
  7. Brettschneider J, Petzold A, Junker A, Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006; 12(2): 143-8.
  8. Sombekke MH, Wattjes MP, Balk LJ, Nielsen JM, Vrenken H, Uitdehaag BM, et al. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 2013; 80(1): 69-75.
  9. Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler 2015; 21(8): 1013-24.
  10. Tabrizi R, Moosazadeh M, Akbari M, Dabbaghmanesh MH, Mohamadkhani M, Asemi Z, et al. High prevalence of vitamin D deficiency among Iranian population: a systematic review and meta-analysis. Iran J Med Sci 2018; 43(2): 125-39.
  11. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007; 179(3): 1634-47.
  12. Li M, Luo L, Lin C, Ni B, Zou L, Song Z, et al. Vitamin D3 mitigates autoimmune inflammation caused by activation of myeloid dendritic cells in SLE. Exp Dermatol 2024; 33(1): e14926.
  13. Dankers W, Colin EM, Van Hamburg JP, Lubberts E. Vitamin D in autoimmunity: molecular mechanisms and therapeutic potential. Front Immunol 2017; 7: 236441.
  14. Koduah P, Paul F, Dörr J-M. Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. EPMA J 2017; 8(4): 313-25.
  15. Mealy MA, Newsome S, Greenberg BM, Wingerchuk D, Calabresi P, Levy M. Low serum vitamin D levels and recurrent inflammatory spinal cord disease. Arch Neurol 2012; 69(3): 352-6.
Journal of Isfahan Medical School
Volume 43, Issue 835
3rd Week,, December
November and December 2026
Pages 1306-1311

Files

History

  • Receive Date: 10 June 2025
  • Revise Date: 07 January 2026
  • Accept Date: 11 August 2025

Share

How to cite

Statistics